. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Pediatr Nephrol. 2013 Jun 20;28(11):2179–2188. doi: 10.1007/s00467-013-2524-6

Table 3.

NGAL, FGF-2, and EGF concentrations expressed per mL of urine.

	Control (n = 27)	Hypothermia (HT) (n = 25)	ECMO (n = 10)	P-value^*

NGAL (ng/ml)
Baseline	63.85 (4.5 −142)	929.0 ^* (290 −1,000)	358.0^{* *} (164 −592)	^* < 0.0001
Baseline	63.85 (4.5 −142)	929.0 ^* (290 −1,000)	358.0^{* *} (164 −592)	^** 0.0007
48hr	n/a	577.5^* (122 −1,000)	241.0^{* *} (81– 935)	^* < 0.0001
48hr	n/a	577.5^* (122 −1,000)	241.0^{* *} (81– 935)	^** 0.0055
Recovery	n/a	181.0^* (49 – 613)	37.0^{* *} (21–100)	^* 0.0033
Recovery	n/a	181.0^* (49 – 613)	37.0^{* *} (21–100)	^** 0.9843

FGF (pg/ml)
Baseline	2.1 (1.2 – 6.8)	10.0^* (3.5 – 15.7)	2.6^** (1.8 – 12.1)	^* 0.0095
Baseline	2.1 (1.2 – 6.8)	10.0^* (3.5 – 15.7)	2.6^** (1.8 – 12.1)	^** 0.5108
48hr	n/a	8.5^* (4.5 – 12.6)	2.5^** (0.7 – 7.7)	^* 0.0012
48hr	n/a	8.5^* (4.5 – 12.6)	2.5^** (0.7 – 7.7)	^** 0.8838
Recovery	n/a	3.6^* (0.9 – 8.7)	2.1^{* *} (0.2 – 3.7)	^* 0.7550
Recovery	n/a	3.6^* (0.9 – 8.7)	2.1^{* *} (0.2 – 3.7)	^** 0.2400

EGF (pg/ml)
Baseline	10,768 (5,991–21,906)	2,141^* (1,225 – 4,503)	5,195^** (869 – 12,302)	^* < 0.0001
Baseline	10,768 (5,991–21,906)	2,141^* (1,225 – 4,503)	5,195^** (869 – 12,302)	^** 0.0616
48hr	n/a	2,393^* (1,515 – 4,377)	3,789^** (2,152 – 4,845)	^* < 0.0001
48hr	n/a	2,393^* (1,515 – 4,377)	3,789^** (2,152 – 4,845)	^** 0.0007
Recovery	n/a	5,762^* (2,911–9,411)	4,875^{* *} (1,497 – 6,284)	^* 0.0044
Recovery	n/a	5,762^* (2,911–9,411)	4,875^{* *} (1,497 – 6,284)	^** 0.0016

NAGL, Neutrophil Gelatinase-associated Lipocalin; FGF, fibroblast growth factor; EGF, epidural growth factor

Data expressed as median (IQR).

P values (* / ** ) compared to the control group (Mann Whitney test).